French biotech GENFIT will receive a $20 million commercial milestone payment after Ipsen reported $208 million in full-year 2025 net sales of Iqirvo in primary biliary cholangitis, surpassing the $200 million threshold set out in the companies’ 2021 licensing agreement.
